PATENT CLAIM ANALYSIS

Application Number: 15918195
Application Type: Utility
Filing Date: 2018-03
Publication Date: 2018-07
Patent Classification: ["514", "210210"]

Abstract:
The present invention provides compounds of Formula (I): or stereoisomers, pharmaceutically acceptable salts thereof, wherein all of the variables are as defined herein. These compounds are inhibitors of factor XIa and/or plasma kallikrein which may be used as medicaments.

Claim (Index 4):
The compound of  claim 3  having formula (III): or a stereoisomer, tautomer, pharmaceutically acceptable salt thereof, wherein:\n R 1a  is selected from the group consisting of: H, halo, C 1-2  alkyl, and methoxy; \n R 1b  is selected from the group consisting of: H and halo; \n R 2  is independently selected from the group consisting of: H, F, CN, OH, C 1-4  alkoxy, \u2014CHF 2 , \u2014CF 3 , \u2014CH 2 NH 2 , \u2014OCHF 2 , \u2014CO(C 1-4  alkyl), \u2014CONH 2 , \u2014COOH, triazole substituted with R 2a , and tetrazole substituted with R 2a ; \n R 3  is selected from the group consisting of: phenyl substituted with 1-2 R 3a , C 3-6  cycloalkyl substituted with 1-2 R 3a , heterocycle substituted with 1-2 R 3a ; wherein said heterocycle is selected from the group consisting of: piperidinyl, pyridyl, indolyl, and indazolyl.

Metadata:
- Claim Count in Document: 15.0
- Percentile: 90.0
- Lexical Diversity: 1.17949
- Patent Class: 514.0
- Transitional Phrase Type: closed
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['14117513', '15361589', '14617979', '14886415', '14350411']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.8627916140791296
- 35 USC 102 Novelty (BERT): 0.6578932557212136
- Combined Prediction Score: 0.8423017782433381
- Mean Citation Score: 542.883702
- Max Citation Score: 635.02765
- Similarity Product: 631.3890342116504

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test